⌘K
t
Dechra Pharmaceuticals PLC announced on 16 February 2022 the appointment of Dr Lawson Macartney as Senior Independent Director. This appointment is effective from 1 March 2022, following Alison Platt's appointment as Chair of the Company on 1 January 2022.
| Date | 16 Feb 2022 |
| Time | 16:23:18 |
| Category | Board changes |
| ID | 9120B |
16 February 2022
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
Senior Independent Director Appointment
Dechra is pleased to announce that, with effect from 1 March 2022, Dr Lawson Macartney will take up the position as Senior Independent Director following the appointment of Alison Platt as Chair of the Company on 1 January 2022.
|
Enquiries: |
|
|
Dechra Pharmaceuticals PLC |
|
|
Ian Page, Chief Executive Officer |
Office: +44 (0) 1606 814 730 |
|
e-mail: [email protected] |
|
|
|
|
|
TooleyStreet Communications Ltd |
|
|
Fiona Tooley, Director e-mail: [email protected] |
Mobile: +44 (0) 7785 703 523 Office: +44 (0) 121 309 0099 |
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Market Abuse Regulation (MAR)
The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.